Docetaxel/ritonavir - Modra Pharmaceuticals
Alternative Names: Docetaxel plus ritonavir - Modra Pharmaceuticals; ModraDoc 006; ModraDoc 006/r; ModraDoc001; ModraDoc003; Oral docetaxel formulation - Modra PharmaceuticalsLatest Information Update: 28 Jul 2024
At a glance
- Originator Modra Pharmaceuticals
- Developer Modra Pharmaceuticals; Netherlands Cancer Institute
- Class Amides; Antineoplastics; Carbamates; Small molecules; Taxanes; Thiazoles
- Mechanism of Action Cytochrome P-450 enzyme system inhibitors; Mitosis inhibitors; P-glycoprotein inhibitors; Tubulin inhibitors; Tubulin polymerisation promoters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Breast cancer; Prostate cancer; Solid tumours
Most Recent Events
- 28 Jul 2024 No recent reports of development identified for phase-I development in Prostate-cancer(Combination therapy, Early-stage disease, Hormone refractory) in Netherlands (PO, Tablet)
- 16 Mar 2023 Modra Pharmaceuticals announces US patent issuance for docetaxel/ritonavir
- 11 Jul 2022 Docetaxel/ritonavir is still in phase I trials for Prostate cancer (Combination therapy, Early-stage disease, Hormone refractory) in Netherlands (Modra Pharmaceuticals pipeline, July 2022)